News
Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development
This book chapter by Dr Philp et al aims to serve as a comprehensive resource for the preparation and adoption of PCa PDX models in the research laboratory and for their use as a valuable preclinical platform for translational research and therapeutic agent development.
Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models
Metformin, the first line pharmacotherapy for type 2 diabetes has demonstrated favourable effects in prostate cancer (PCa) across a range of studies evaluating PCa patient outcomes amongst metformin users. This review by Dr Gunter et al highlights the potential of metformin to be repurposed as an anticancer agent, warranting further investigation of metformin in the setting of PCa.
Movember 2023 Fundraising Sale
Great team effort for our Movember 2023 Fundraising sale - making a difference in the community, in research and in peoples’ lives!
PAH Giving Day 2023 Bake Sale
Our amazing team has raised $2702 from our bake sale to support the Princess Alexandra Hospital Giving Day 2023.
Gene expression based inference of cancer drug sensitivity
In this study, we introduce Precily, a predictive modeling approach to infer treatment response in cancers using gene expression data. We assessed the predictability of treatment outcomes and demonstrated the applicability of our approach on patient drug response data.
Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation
Our research by Dr Tang et al associates NRP1 expression with shorter relapse- and metastasis-free survival, which implicates NRP1 with the aggressive phenotype of claudin-low breast cancer and offers a novel targeted therapeutic approach to this poor prognosis subtype.
Leptin antagonism inhibits prostate cancer xenograft growth and progression
Our study by Dr Philp et al reveals the world-first preclinical evidence that demonstrates marked efficacy of targeted leptin-signalling blockade, using Allo-aca, a potent, specific, and safe LEPR peptide antagonist. This highlights LEPR blockade in combination with androgen axis inhibition as a promising new therapeutic strategy vital in advanced PCa treatment.
PA Giving Day PA Prostate Team Fundraising a Great Success
The APCRC-Q PA Prostate Cancer team had a engaging 2nd Sept 2021, raising funds for the PA Giving Day We’re all 4 the Heroes campaign.
APCRC-Q Founder and Executive Director Professor Colleen Nelson Celebrated in Australia Day 2021 Honours
Professor Colleen Nelson has been appointed a Member of the Order of Australia, for significant service to medical research, particularly prostate cancer, and to health organisations, in the 2021 Australia Day Honours.
New prostate cancer therapeutics being developed by APCRC-Q researchers could also fight COVID-19
Therapies being developed by the Centre's Dr Lisa Philp and Professor Colleen Nelson for prostate cancer, could also be used to fight the worst symptoms of COVID-19.
APCRC-Q researchers provide commentary on recent cancer publications
A suite of 23 articles recently published in Nature and its affiliated journals detailed the results of research conducted by the Pan-Cancer Analysis of Whole Genomes Consortium.
2019 Carla Patterson Award Winners
Congratulations to Dr Sri Srinivasan and Ms Farhana Martin on their recent success winning 2019 Carla Patterson Awards.
Movember Fundraising a Great Success
The month of Movember is a busy one for APCRC-Q as we go into overdrive raising funds for a cause that is close to all our hearts – men’s health.
APCRC-Q researchers receive a Metro South Health Research Support Scheme Grant
Congratulations to Dr Ian Vela, A/Prof Elizabeth Williams, Dr Patrick Thomas, and Dr Ben Shepherd who were awarded an Innovation (Seed) Grant of $25,000
APCRC-Q Research featured in Top Story of Prostate Cell News
Congratulations to Nathalie Bock, Ali Shokoohmand, Thomas Kryza, Joan Röhl, Jonelle Meijer, Phong A. Tran, Colleen C. Nelson, Judith A. Clements and Dietmar W. Hutmacher. Their article entitled: “Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment” was featured as Top Story in the 26 April 2019 issue of Prostate Cancer Cell News.
MicroRNA Profiling Reveals Prostate Cancer Diagnostic Biomarker Panel
APCRC-Q PhD candidate, Farhana Martin, and A/Prof Jyotsna Batra have identified a four microRNA signature with the potential to improve early prostate cancer diagnosis.
United States Department of Defence Funding Award for APCRC-Q Research team
APCRC-Q researchers awarded a US Department of Defense Idea Development Award.
A/Prof Jyotsna Batra featured in Newspaper in India
A/Prof Jyostna Batra received media coverage while in India last month for the International Conference on Translational Research.
Movember Fundraising Success
Congratulations to the APCRC-Q team who raised a total of $3497 dollars during Movember this year.
